{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:18:34Z","timestamp":1792919914441,"version":"4.5.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"21","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,21]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with relapsed\/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) have poor outcomes compared with newly diagnosed, treatment-na\u00efve patients. The phase 2, open-label DELPHINUS study evaluated daratumumab (16 mg\/kg IV) plus backbone chemotherapy in children with relapsed\/refractory B-cell ALL (n\u00a0=\u00a07) after \u22652 relapses, and children and young adults with T-cell ALL (children, n\u00a0=\u00a024; young adults, n\u00a0=\u00a05) or LL (n\u00a0=\u00a010) after first relapse. The primary end point was complete response (CR) in the B-cell ALL (end of cycle 2) and T-cell ALL (end of cycle 1) cohorts, after which patients could proceed off study to allogeneic hematopoietic stem cell transplant (HSCT). Seven patients with advanced B-cell ALL received daratumumab with no CRs achieved; this cohort was closed because of futility. For the childhood T-cell ALL, young adult T-cell ALL, and T-cell LL cohorts, the CR (end of cycle 1) rates were 41.7%, 60.0%, and 30.0%, respectively; overall response rates (any time point) were 83.3% (CR\u00a0+ CR with incomplete count recovery [CRi]), 80.0% (CR\u00a0+ CRi), and 50.0% (CR\u00a0+ partial response), respectively; minimal residual disease negativity (&amp;lt;0.01%) rates were 45.8%, 20.0%, and 50.0%, respectively; observed 24-month event-free survival rates were 36.1%, 20.0%, and 20.0%, respectively; observed 24-month overall survival rates were 41.3%, 25.0%, and 20.0%, respectively; and allogeneic HSCT rates were 75.0%, 60.0%, and 30.0%, respectively. No new safety concerns with daratumumab were observed. In conclusion, daratumumab was safely combined with backbone chemotherapy in children and young adults with T-cell ALL\/LL and contributed to successful bridging to HSCT. This trial was registered at www.clinicaltrials.gov as NCT03384654.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024024493","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T07:20:59Z","timestamp":1724052059000},"page":"2237-2247","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":68,"title":["Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study"],"prefix":"10.1182","volume":"144","author":[{"given":"Teena","family":"Bhatla","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Children\u2019s Hospital of New Jersey, Newark Beth Israel Medical Center, Newark, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Hogan","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, Stony Brook Children\u2019s, Stony Brook, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-8987","authenticated-orcid":false,"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Center for Childhood Cancer Research, Children\u2019s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-8862","authenticated-orcid":false,"given":"Francisco","family":"Bautista","sequence":"additional","affiliation":[{"name":"4Department of Pediatric Hematology-Oncology, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"5Department of Pediatric Hematology-Oncology, Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1844-3531","authenticated-orcid":false,"given":"John","family":"Moppett","sequence":"additional","affiliation":[{"name":"6Paediatric Haematology, Bristol Royal Hospital for Children, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7331-9483","authenticated-orcid":false,"given":"Pablo","family":"Velasco Puy\u00f3","sequence":"additional","affiliation":[{"name":"7Department of Pediatric Hematology-Oncology, Vall d\u2019Hebron Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Micalizzi","sequence":"additional","affiliation":[{"name":"8Clinical Experimental Haematology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-5285","authenticated-orcid":false,"given":"Claudia","family":"Rossig","sequence":"additional","affiliation":[{"name":"9Department of Pediatric Hematology and Oncology, University Children\u2019s Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerav","family":"Shukla","sequence":"additional","affiliation":[{"name":"10Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6120-3527","authenticated-orcid":false,"given":"Gil","family":"Gilad","sequence":"additional","affiliation":[{"name":"11Department of Pediatric Hematology-Oncology, Schneider Children\u2019s Medical Center of Israel, Petach Tikva, Israel"},{"name":"12Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"13Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Ges\u00f9, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0120-6089","authenticated-orcid":false,"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[{"name":"14Pediatric Hematology and Immunology Department, Robert Debr\u00e9 University Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris and Universit\u00e9 de Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[{"name":"4Department of Pediatric Hematology-Oncology, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"15Department of Pediatric Oncology, Erasmus MC-Sophia Children\u2019s Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7093-8713","authenticated-orcid":false,"given":"Natalie S.","family":"Bezler","sequence":"additional","affiliation":[{"name":"16Division of Hematology and Oncology, Connecticut Children\u2019s, University of Connecticut School of Medicine, Hartford, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-7423","authenticated-orcid":false,"given":"Alba","family":"Rubio-San-Sim\u00f3n","sequence":"additional","affiliation":[{"name":"5Department of Pediatric Hematology-Oncology, Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Taussig","sequence":"additional","affiliation":[{"name":"17Centre for Molecular Pathology, The Royal Marsden Hospital, Institute of Cancer Research, Sutton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Raetz","sequence":"additional","affiliation":[{"name":"18Department of Pediatrics, New York University Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei J.","family":"Mao","sequence":"additional","affiliation":[{"name":"19Department of Laboratory Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent L.","family":"Wood","sequence":"additional","affiliation":[{"name":"19Department of Laboratory Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Alvarez Arias","sequence":"additional","affiliation":[{"name":"20Janssen Research and Development, LLC, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Krevvata","sequence":"additional","affiliation":[{"name":"20Janssen Research and Development, LLC, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Nnane","sequence":"additional","affiliation":[{"name":"20Janssen Research and Development, LLC, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nibedita","family":"Bandyopadhyay","sequence":"additional","affiliation":[{"name":"21Janssen Research and Development, LLC, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Lopez Solano","sequence":"additional","affiliation":[{"name":"21Janssen Research and Development, LLC, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn M.","family":"Dennis","sequence":"additional","affiliation":[{"name":"21Janssen Research and Development, LLC, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[{"name":"20Janssen Research and Development, LLC, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Vora","sequence":"additional","affiliation":[{"name":"22Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2024112116204644500_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fonc.2020.00273","article-title":"The physiopathology of T- cell acute lymphoblastic leukemia: focus on molecular aspects","volume":"10","author":"Fattizzo","year":"2020","journal-title":"Front Oncol"},{"issue":"7","key":"2024112116204644500_bib2","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/pbc.25990","article-title":"Relapsed or refractory lymphoblastic lymphoma in children: results and analysis of 23 patients in the EORTC 58951 and the LMT96 protocols","volume":"63","author":"Michaux","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"26","key":"2024112116204644500_bib3","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.20.00531","article-title":"Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from Children's Oncology Group AALL0434","volume":"38","author":"Hayashi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024112116204644500_bib4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2141.2008.07499.x","article-title":"Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Munster (BFM) Study Group","volume":"144","author":"Reismuller","year":"2009","journal-title":"Br J Haematol"},{"issue":"12","key":"2024112116204644500_bib5","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"2024112116204644500_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.12.029","article-title":"Targeted inhibitors and antibody immunotherapies: novel therapies for paediatric leukaemia and lymphoma","volume":"164","author":"Brivio","year":"2022","journal-title":"Eur J Cancer"},{"issue":"9","key":"2024112116204644500_bib7","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"2024112116204644500_bib8","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study","volume":"28","author":"Ko","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024112116204644500_bib9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"issue":"14","key":"2024112116204644500_bib10","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group","volume":"30","author":"Hunger","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2024112116204644500_bib11","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024112116204644500_bib12","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9","key":"2024112116204644500_bib13","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024112116204644500_bib14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"2024112116204644500_bib15","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial","volume":"36","author":"Pennesi","year":"2022","journal-title":"Leukemia"},{"issue":"19","key":"2024112116204644500_bib16","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2005.04.5856","article-title":"Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941","volume":"24","author":"Gaynon","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2024112116204644500_bib17","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024112116204644500_bib18","doi-asserted-by":"crossref","first-page":"e29901","DOI":"10.1002\/pbc.29901","article-title":"Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR)","volume":"69","author":"Whitlock","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2024112116204644500_bib19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2024112116204644500_bib20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/bjh.14310","article-title":"CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy","volume":"180","author":"Bras","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"2024112116204644500_bib21","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"21","key":"2024112116204644500_bib22","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in\u00a0vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79","volume":"124","author":"Lammerts van Bueren","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2024112116204644500_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"issue":"3","key":"2024112116204644500_bib24","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"2024112116204644500_bib25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2024112116204644500_bib26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.a.23693","article-title":"High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action","volume":"95","author":"Adams","year":"2019","journal-title":"Cytometry A"},{"issue":"2","key":"2024112116204644500_bib27","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","article-title":"Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab","volume":"35","author":"Casneuf","year":"2021","journal-title":"Leukemia"},{"key":"2024112116204644500_bib28","volume-title":"DARZALEX\u00ae (daratumumab) injection, for intravenous use. Package insert","year":"2023"},{"key":"2024112116204644500_bib29","volume-title":"DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj). Package insert","year":"2022"},{"issue":"8","key":"2024112116204644500_bib30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019000904","article-title":"Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia","volume":"134","author":"Vogiatzi","year":"2019","journal-title":"Blood"},{"key":"2024112116204644500_bib31","unstructured":"National Comprehensive Cancer Network\n          . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Acute Lymphoblastic Leukemia, V2.2016. Accessed 17 May 2017. http:\/\/NCCN.org."},{"issue":"4","key":"2024112116204644500_bib32","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2024112116204644500_bib33","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024112116204644500_bib34","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/bloodadvances.2022008280","article-title":"Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv"},{"issue":"10218","key":"2024112116204644500_bib35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"2024112116204644500_bib36","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of\u00a0POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2024112116204644500_bib37","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/cpt.577","article-title":"Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients\u00a0with relapsed\/refractory multiple myeloma","volume":"101","author":"Xu","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2024112116204644500_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1208\/s12248-009-9157-5","article-title":"Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease","volume":"12","author":"Tabrizi","year":"2010","journal-title":"AAPS J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/21\/2237\/2314026\/blood_bld-2024-024493-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/21\/2237\/2314026\/blood_bld-2024-024493-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T11:21:02Z","timestamp":1732188062000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/21\/2237\/517403\/Daratumumab-in-pediatric-relapsed-refractory-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":38,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,11,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024493","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}